Birdwatch Note
2024-11-23 06:08:44 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
売却は発行済み株式総数のわずか約4.7%です。 今後の計画の発表であり、価格が下がる前に売り抜けるような話ではありません https://www.nikkei.com/article/DGXZQOUC228BU0S4A121C2000000/ コスタイベ(レプリコン)の安全性と有効性は治験で良好と評価されています。 死亡はプラセボ群が16(うち、新型コロナ9)接種群では5(うち、新型コロナ1)と減少しており、特段の懸念は認められません https://doi.org/10.1038/s41467-024-47905-1 https://www.mhlw.go.jp/content/10906000/001316061.pdf https://www.pmda.go.jp/drugs/2024/P20240917001/780009000_30500AMX00282_A100_1.pdf https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#20 治験結果で承認して市販後調査で再審査するのは薬機法第14条および第14条の4に定められた通常の手続きです https://laws.e-gov.go.jp/law/335AC0000000145#Mp-Ch_4-At_14 https://laws.e-gov.go.jp/law/335AC0000000145#Mp-Ch_4-At_14_4 https://x.com/Meiji_Seika_p/status/1856988064805171608 「適当な治験」「中長期的副作用」の根拠も示されていません。 根拠のない妄想の「ガン無視」は当然です
Written by EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1860013280032620842
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1860203814558793778
- noteId - 1860203814558793778
- participantId -
- noteAuthorParticipantId - EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00 Participant Details
- createdAtMillis - 1732342124963
- tweetId - 1860013280032620842
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 1
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 売却は発行済み株式総数のわずか約4.7%です。 今後の計画の発表であり、価格が下がる前に売り抜けるような話ではありません https://www.nikkei.com/article/DGXZQOUC228BU0S4A121C2000000/ コスタイベ(レプリコン)の安全性と有効性は治験で良好と評価されています。 死亡はプラセボ群が16(うち、新型コロナ9)接種群では5(うち、新型コロナ1)と減少しており、特段の懸念は認められません https://doi.org/10.1038/s41467-024-47905-1 https://www.mhlw.go.jp/content/10906000/001316061.pdf https://www.pmda.go.jp/drugs/2024/P20240917001/780009000_30500AMX00282_A100_1.pdf https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#20 治験結果で承認して市販後調査で再審査するのは薬機法第14条および第14条の4に定められた通常の手続きです https://laws.e-gov.go.jp/law/335AC0000000145#Mp-Ch_4-At_14 https://laws.e-gov.go.jp/law/335AC0000000145#Mp-Ch_4-At_14_4 https://x.com/Meiji_Seika_p/status/1856988064805171608 「適当な治験」「中長期的副作用」の根拠も示されていません。 根拠のない妄想の「ガン無視」は当然です
Note Ratings
| rated at | rated by | |
| 2024-11-25 06:15:58 -0600 | Rating Details | |
| 2024-11-25 01:05:20 -0600 | Rating Details | |
| 2024-11-24 22:39:25 -0600 | Rating Details | |
| 2024-11-24 12:17:59 -0600 | Rating Details | |
| 2024-11-24 10:41:54 -0600 | Rating Details | |
| 2024-11-24 10:32:20 -0600 | Rating Details | |
| 2024-11-24 10:01:54 -0600 | Rating Details | |
| 2024-11-24 08:21:21 -0600 | Rating Details | |
| 2024-11-24 07:20:23 -0600 | Rating Details | |
| 2024-11-24 07:17:05 -0600 | Rating Details | |
| 2024-11-24 07:10:58 -0600 | Rating Details | |
| 2024-11-24 05:00:16 -0600 | Rating Details | |
| 2024-11-24 04:30:43 -0600 | Rating Details | |
| 2024-11-24 02:57:18 -0600 | Rating Details | |
| 2024-11-24 02:25:19 -0600 | Rating Details | |
| 2024-11-24 02:22:28 -0600 | Rating Details | |
| 2024-11-24 01:21:02 -0600 | Rating Details | |
| 2024-11-24 01:17:19 -0600 | Rating Details | |
| 2024-11-24 00:39:08 -0600 | Rating Details | |
| 2024-11-23 22:19:10 -0600 | Rating Details | |
| 2024-11-23 21:42:29 -0600 | Rating Details | |
| 2024-11-23 19:29:06 -0600 | Rating Details | |
| 2024-11-23 19:16:15 -0600 | Rating Details | |
| 2024-11-23 18:17:28 -0600 | Rating Details | |
| 2024-11-23 18:17:24 -0600 | Rating Details | |
| 2024-11-23 18:05:24 -0600 | Rating Details | |
| 2024-11-23 17:57:10 -0600 | Rating Details | |
| 2024-11-23 17:52:21 -0600 | Rating Details | |
| 2024-11-23 16:19:11 -0600 | Rating Details | |
| 2024-11-23 15:57:26 -0600 | Rating Details | |
| 2024-11-23 15:45:30 -0600 | Rating Details | |
| 2024-11-23 15:43:34 -0600 | Rating Details | |
| 2024-11-23 14:51:55 -0600 | Rating Details | |
| 2024-11-23 14:46:39 -0600 | Rating Details | |
| 2024-11-23 11:02:25 -0600 | Rating Details | |
| 2024-11-23 10:17:51 -0600 | Rating Details | |
| 2024-11-23 10:10:07 -0600 | Rating Details | |
| 2024-11-23 09:58:39 -0600 | Rating Details | |
| 2024-11-23 09:53:22 -0600 | Rating Details | |
| 2024-11-23 08:37:22 -0600 | Rating Details | |
| 2024-11-23 08:26:08 -0600 | Rating Details | |
| 2024-11-23 08:22:22 -0600 | Rating Details | |
| 2024-11-23 08:01:27 -0600 | Rating Details | |
| 2024-11-23 08:00:36 -0600 | Rating Details | |
| 2024-11-23 07:46:55 -0600 | Rating Details | |
| 2024-11-23 07:07:24 -0600 | Rating Details | |
| 2024-11-23 06:58:23 -0600 | Rating Details | |
| 2024-11-23 06:11:00 -0600 | Rating Details | |
| 2024-11-23 05:54:42 -0600 | Rating Details | |
| 2024-11-23 05:47:48 -0600 | Rating Details | |
| 2024-11-23 05:46:01 -0600 | Rating Details | |
| 2024-11-23 04:46:03 -0600 | Rating Details | |
| 2024-11-23 04:28:49 -0600 | Rating Details | |
| 2024-11-23 04:20:11 -0600 | Rating Details | |
| 2024-11-23 03:58:41 -0600 | Rating Details | |
| 2024-11-23 03:52:45 -0600 | Rating Details | |
| 2024-11-23 03:43:24 -0600 | Rating Details | |
| 2024-11-23 03:38:17 -0600 | Rating Details | |
| 2024-11-23 03:24:33 -0600 | Rating Details | |
| 2024-11-23 03:17:13 -0600 | Rating Details | |
| 2024-11-23 02:57:23 -0600 | Rating Details | |
| 2024-11-23 02:55:02 -0600 | Rating Details | |
| 2024-11-23 02:47:40 -0600 | Rating Details | |
| 2024-11-23 02:40:57 -0600 | Rating Details | |
| 2024-11-23 02:11:00 -0600 | Rating Details | |
| 2024-11-23 02:06:41 -0600 | Rating Details | |
| 2024-11-23 02:04:28 -0600 | Rating Details | |
| 2024-11-23 02:02:28 -0600 | Rating Details | |
| 2024-11-23 01:59:57 -0600 | Rating Details | |
| 2024-11-23 01:58:39 -0600 | Rating Details | |
| 2024-11-23 01:49:46 -0600 | Rating Details | |
| 2024-11-23 01:42:13 -0600 | Rating Details | |
| 2024-11-23 01:21:03 -0600 | Rating Details | |
| 2024-11-23 01:16:11 -0600 | Rating Details | |
| 2024-11-23 01:01:23 -0600 | Rating Details | |
| 2024-11-23 00:41:38 -0600 | Rating Details | |
| 2024-11-23 00:27:24 -0600 | Rating Details | |
| 2024-11-23 00:19:43 -0600 | Rating Details | |
| 2024-11-26 08:42:31 -0600 | Rating Details | |
| 2024-11-25 16:55:40 -0600 | Rating Details | |
| 2024-11-25 02:06:40 -0600 | Rating Details | |
| 2024-11-25 01:25:56 -0600 | Rating Details | |
| 2024-11-24 21:34:13 -0600 | Rating Details | |
| 2024-11-24 15:24:49 -0600 | Rating Details | |
| 2024-11-24 08:48:23 -0600 | Rating Details | |
| 2024-11-24 07:19:42 -0600 | Rating Details | |
| 2024-11-24 07:00:39 -0600 | Rating Details | |
| 2024-11-24 04:12:11 -0600 | Rating Details | |
| 2024-11-24 03:14:27 -0600 | Rating Details | |
| 2024-11-24 03:02:04 -0600 | Rating Details | |
| 2024-11-24 02:06:25 -0600 | Rating Details | |
| 2024-11-24 01:59:48 -0600 | Rating Details | |
| 2024-11-24 01:47:54 -0600 | Rating Details | |
| 2024-11-24 01:01:45 -0600 | Rating Details | |
| 2024-11-23 23:23:24 -0600 | Rating Details | |
| 2024-11-23 22:26:18 -0600 | Rating Details | |
| 2024-11-23 22:18:58 -0600 | Rating Details | |
| 2024-11-23 22:00:50 -0600 | Rating Details | |
| 2024-11-23 17:49:09 -0600 | Rating Details | |
| 2024-11-23 15:24:01 -0600 | Rating Details | |
| 2024-11-23 10:02:13 -0600 | Rating Details | |
| 2024-11-23 08:47:03 -0600 | Rating Details | |
| 2024-11-23 08:26:06 -0600 | Rating Details | |
| 2024-11-23 07:53:05 -0600 | Rating Details | |
| 2024-11-23 07:19:11 -0600 | Rating Details | |
| 2024-11-23 06:57:11 -0600 | Rating Details | |
| 2024-11-23 06:35:23 -0600 | Rating Details | |
| 2024-11-23 06:07:27 -0600 | Rating Details | |
| 2024-11-23 05:52:11 -0600 | Rating Details | |
| 2024-11-23 05:44:48 -0600 | Rating Details | |
| 2024-11-23 04:44:26 -0600 | Rating Details | |
| 2024-11-23 04:40:27 -0600 | Rating Details | |
| 2024-11-23 03:37:47 -0600 | Rating Details | |
| 2024-11-23 03:08:59 -0600 | Rating Details | |
| 2024-11-23 02:50:03 -0600 | Rating Details | |
| 2024-11-23 02:34:52 -0600 | Rating Details | |
| 2024-11-23 01:38:42 -0600 | Rating Details | |
| 2024-11-23 01:19:57 -0600 | Rating Details | |
| 2024-11-23 00:55:59 -0600 | Rating Details | |
| 2024-11-23 00:47:33 -0600 | Rating Details | |
| 2024-11-23 00:26:07 -0600 | Rating Details |